Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Rucaparib |
Synonyms | |
Therapy Description |
Rubraca (rucaparib) binds to and inhibits PARP, which may result in accumulation of DNA damage and chemosensitization of tumor cells (PMID: 17363489). Rubraca (rucaparib) is FDA approved for use as maintenance therapy in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring a deleterious BRCA mutation, and for treatment in patients with metastatic castration-resistant prostate cancer harboring a deleterious BRCA mutation (germline and/or somatic) who received anti-androgen therapy and a taxane-based therapy (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Rucaparib | Rubraca | AG014699|PF-01367338|CO-388|AG14447 | PARP Inhibitor (Pan) 31 | Rubraca (rucaparib) binds to and inhibits PARP, which may result in accumulation of DNA damage and chemosensitization of tumor cells (PMID: 17363489). Rubraca (rucaparib) is FDA approved for use as maintenance therapy in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring a deleterious BRCA mutation, and for treatment in patients with metastatic castration-resistant prostate cancer harboring a deleterious BRCA mutation (germline and/or somatic) who received anti-androgen therapy and a taxane-based therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PALB2 inact mut | biliary tract cancer | sensitive | Rucaparib | Guideline | Actionable | Rubraca (rucaparib) is included in the Pan-Asian Guidelines Adaptation (PAGA) for platinum-sensitive biliary tract cancer patients harboring PALB2 mutations (PMID: 39232586; ESMO.org). | detail... 39232586 |
PALB2 inact mut | biliary tract cancer | sensitive | Rucaparib | Guideline | Actionable | Rubraca (rucaparib) is included in guidelines as second or later-line therapy for patients with biliary tract cancer harboring PALB2 mutations (PMID: 39864891; ESMO.org). | 39864891 detail... |
PALB2 mutant | pancreatic adenocarcinoma | sensitive | Rucaparib | Guideline | Actionable | Rubraca (rucaparib) is included in guidelines as maintenance therapy following prior platinum-based therapy for patients with metastatic pancreatic adenocarcinoma harboring germline or somatic PALB2 mutations (NCCN.org). | detail... |
ATM inact mut | prostate cancer | no benefit | Rucaparib | Phase III | Actionable | In a Phase III trial (TRITON3), Rubraca (rucaparib) treatment demonstrated limited efficacy compared to control treatment with Taxotere (docetaxel) in patients with metastatic castration-resistant prostate cancer harboring deleterious ATM mutations, with a median imaging-based progression-free survival of 8.1 months vs. 6.8 months (HR=0.95), a median overall survival of 21.1 months vs. 21.7 months of patients (PMID: 36795891; NCT02975934). | 36795891 |
ATM inact mut | prostate cancer | no benefit | Rucaparib | Phase II | Actionable | In a Phase II trial (TRITON2), activity of Rubraca (rucaparib) was limited in the cohort of patients with metastatic castrate-resistant prostate cancer harboring an ATM mutation presumed to be inactivating, with a radiographic response rate of 10.5% (2/19, including 1 patient with co-occurring CHEK2 alteration) and PSA response rate of 4.1% (2/49), and no radiographic responses in 11 patients with biallelic alterations in ATM or 11 patients with germline ATM alterations (PMID: 32086346; NCT02952534). | 32086346 |
CDK12 inact mut | prostate cancer | no benefit | Rucaparib | Phase II | Actionable | In a Phase II trial (TRITON2), activity of Rubraca (rucaparib) was limited in the cohort of patients with metastatic castrate-resistant prostate cancer harboring a CDK12 mutation presumed to be inactivating, with no confirmed radiographic responses in 10 evaluable patients and a PSA response in 1 patient with biallelic CDK12 alterations in the overall population of 15 patients, and a clinical benefit rate of 20% (3/15) at 6 months and 7.1% (1/14) at 12 months (PMID: 32086346; NCT02952534). | 32086346 |
CHEK2 inact mut | prostate cancer | no benefit | Rucaparib | Phase II | Actionable | In a Phase II trial (TRITON2), activity of Rubraca (rucaparib) was limited in the cohort of patients with metastatic castrate-resistant prostate cancer harboring a CHEK2 mutation presumed to be inactivating, with a radiographic partial response in 1 patient who had a co-occurring ATM alteration out of 9 evaluable patients, and PSA response rate of 16.7% (2/12), and a clinical benefit rate of 37.5% (3/8) at 6 months, with no patients remaining on treatment at 12 months (PMID: 32086346; NCT02952534). | 32086346 |
BRIP1 inact mut | prostate cancer | predicted - sensitive | Rucaparib | Case Reports/Case Series | Actionable | In a Phase II trial (TRITON2), 1 of 2 patients with metastatic castrate-resistant prostate cancer harboring deleterious BRIP1 alterations demonstrated a PSA response and partial radiographic response after treatment with Rubraca (rucaparib), which were ongoing at the time of visit cutoff (PMID: 32086346; NCT02952534). | 32086346 |
FANCA inact mut | prostate cancer | predicted - sensitive | Rucaparib | Case Reports/Case Series | Actionable | In a Phase II trial, 1 of 4 patients with metastatic castrate-resistant prostate cancer harboring deleterious FANCA alterations demonstrated a PSA response and complete radiographic response after treatment with Rubraca (rucaparib), which were ongoing at the time of visit cutoff (PMID: 32086346; NCT02952534). | 32086346 |
PALB2 inact mut | pancreatic cancer | predicted - sensitive | Rucaparib | Case Reports/Case Series | Actionable | In a Phase II trial, maintenance Rubraca (rucaparib) resulted in a median progression-free survival (mPFS) of 13.1 months and an objective response rate (ORR) of 41.7% (15/36, 3 complete responses, 12 partial responses) in patients with platinum-sensitive, advanced pancreatic cancer harboring deleterious mutations in BRCA1/2 or PALB2, ORR was 50% (3/6) in patients with PALB2 mutations (PMID: 33970687; NCT03140670). | 33970687 |
PALB2 inact mut | prostate cancer | predicted - sensitive | Rucaparib | Case Reports/Case Series | Actionable | In a Phase II trial (TRITON2), 2 of 2 patients with metastatic castrate-resistant prostate cancer harboring deleterious PALB2 alterations demonstrated a PSA response after treatment with Rubraca (rucaparib), with one of those patients demonstrating partial radiographic response that was ongoing 3.9 months, and the other a 47% reduction in tumor volume (PMID: 32086346; NCT02952534). | 32086346 |
RAD51B rearrange | prostate cancer | predicted - sensitive | Rucaparib | Case Reports/Case Series | Actionable | In a Phase II trial (TRITON2), a patient with metastatic castrate-resistant prostate cancer harboring a RAD51B rearrangement demonstrated a PSA response and partial radiographic response after treatment with Rubraca (rucaparib), which were ongoing at the time of visit cutoff (PMID: 32086346; NCT02952534). | 32086346 |
RAD51C H192_R193delinsGG RAD51C R193* RAD51C R193L RAD51C R193W | ovarian carcinoma | predicted - resistant | Rucaparib | Case Reports/Case Series | Actionable | In a clinical case study, an ovarian carcinoma patient harboring a RAD51C R193* germline mutation developed resistance to Rubraca (rucaparib) after acquisition of RAD51C R193W, RAD51C H192_R193delinsGG, and RAD51C R193L (PMID: 28588062). | 28588062 |
RAD51C R193* | ovarian carcinoma | predicted - sensitive | Rucaparib | Case Reports/Case Series | Actionable | In a clinical case study, an ovarian carcinoma patient harboring a RAD51C R193* germline mutation demonstrated a partial response when treated with Rubraca (rucaparib) (PMID: 28588062). | 28588062 |
RAD51D S257_R259delinsK RAD51D G258Sfs*50 | ovarian carcinoma | predicted - resistant | Rucaparib | Case Reports/Case Series | Actionable | In a clinical case study, an ovarian carcinoma patient harboring a RAD51D G258Sfs*50 germline mutation developed resistance to Rubraca (rucaparib) after acquisition of RAD51D S257_R259delinsK (PMID: 28588062). | 28588062 |
CDK12 del | prostate cancer | sensitive | Rucaparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Rubraca (rucaparib) treatment inhibited viability of prostate cancer cell lines with biallelic CDK12 truncations in culture and inhibited tumor growth in a cell line xenograft model (PMID: 39321214). | 39321214 |
PTEN Y174H PTEN K263* | colorectal cancer | predicted - sensitive | Rucaparib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Rubraca (rucaparib) inhibited cell proliferation in a patient-derived colorectal cancer organoids harboring PTEN Y174H and K263*, along with PIK3CA N1068fs, in culture (PMID: 32376656). | 32376656 |
ARID1A dec exp | breast cancer | sensitive | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Rubraca (rucaparib) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190). | 26069190 |
ARID1A Q456* | colorectal cancer | sensitive | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Rubraca (rucaparib) treatment resulted in increased apoptosis of colorectal cancer cells harboring ARID1A Q456* in culture (PMID: 26069190). | 26069190 |
ATM del | prostate cancer | no benefit | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, ATM-deficient prostate cancer cell lines did not respond to treatment with Rubraca (rucaparib) in culture (PMID: 32127357). | 32127357 |
CDK12 K1021* | prostate cancer | sensitive | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Rubraca (rucaparib) treatment inhibited viability of a CDK12 knockout prostate cancer cell line expressing CDK12 K1021* in culture (PMID: 39321214). | 39321214 |
CDK12 R701* | prostate cancer | sensitive | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Rubraca (rucaparib) treatment inhibited viability of a CDK12 knockout prostate cancer cell line expressing CDK12 R701* in culture (PMID: 39321214). | 39321214 |
CDK12 R858W | prostate cancer | decreased response | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, expression of CDK12 R858W in CDK12 knockout prostate cancer cell lines demonstrated reduced sensitivity to Rubraca (rucaparib) compared cells with the CDK12 knockout alone in culture (PMID: 39321214). | 39321214 |
CDK12 V387* | prostate cancer | sensitive | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Rubraca (rucaparib) treatment inhibited viability of a CDK12 knockout prostate cancer cell line expressing CDK12 V387* in culture (PMID: 39321214). | 39321214 |
IDH1 R132H | Advanced Solid Tumor | sensitive | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Rubraca (rucaparib)-induced growth inhibition in culture (PMID: 28148839). | 28148839 |
PTEN del | prostate cancer | sensitive | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Rubraca (rucaparib) induced senescence and increased radiosensitivity in PTEN null prostate cancer cells in culture (PMID: 23565244). | 23565244 |
RAD51C H192_R193delinsGG | ovarian carcinoma | resistant | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian carcinoma cells expressing RAD51C H192_R193delinsGG demonstrated resistance to Rubraca (rucaparib) in culture (PMID: 28588062). | 28588062 |
RAD51C R193L | ovarian carcinoma | resistant | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian carcinoma cells expressing RAD51C R193L demonstrated resistance to Rubraca (rucaparib) in culture (PMID: 28588062). | 28588062 |
RAD51C R193W | ovarian carcinoma | resistant | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian carcinoma cells expressing RAD51C R193W demonstrated resistance to Rubraca (rucaparib) in culture (PMID: 28588062). | 28588062 |
RAD51D G258Sfs*50 | ovarian carcinoma | sensitive | Rucaparib | Preclinical - Cell culture | Actionable | In a clinical study, an ovarian carcinoma patient harboring a RAD51D G258Sfs*50 germline mutation demonstrated stable disease when treated with Rubraca (rucaparib) (PMID: 28588062). | 28588062 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02678182 | Phase II | Durvalumab Rucaparib Capecitabine Trastuzumab Capecitabine + Ramucirumab | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial (PLATFORM) | Active, not recruiting | GBR | 0 |
NCT03522246 | Phase III | Rucaparib Nivolumab Nivolumab + Rucaparib | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NZL | ITA | ISR | IRL | GRC | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUS | 5 |
NCT03542175 | Phase I | Rucaparib | A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy | Active, not recruiting | USA | 0 |
NCT03617679 | Phase I | Rucaparib | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT01482715 | Phase Ib/II | Rucaparib | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | Completed | USA | ISR | GBR | ESP | CAN | 0 |
NCT01891344 | Phase II | Rucaparib | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Completed | USA | GBR | FRA | ESP | CAN | AUS | 0 |
NCT01968213 | Phase III | Rucaparib | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Completed | USA | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 0 |
NCT02042378 | Phase II | Rucaparib | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | Completed | USA | ISR | 0 |
NCT02855944 | Phase III | Cisplatin Rucaparib Carboplatin Gemcitabine Paclitaxel | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Completed | USA | POL | ITA | ISR | HUN | GBR | ESP | CZE | CAN | BRA | 2 |
NCT02952534 | Phase II | Rucaparib | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2) | Completed | USA | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 0 |
NCT02975934 | Phase III | Rucaparib Docetaxel Enzalutamide Abiraterone | A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) | Completed | USA | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 0 |
NCT03318445 | Phase I | Rucaparib Irinotecan + Rucaparib | Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | Completed | USA | 0 |
NCT03413995 | Phase II | Rucaparib | Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH) | Completed | USA | 0 |
NCT03845296 | Phase II | Rucaparib | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | Completed | USA | 0 |
NCT03911453 | Phase I | Rucaparib | Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | Completed | USA | 0 |
NCT04227522 | Phase III | Rucaparib | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients (MAMOC) | Completed | DEU | 0 |
NCT04676334 | Phase III | Rucaparib | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R) | Completed | POL | ITA | ISR | GBR | CAN | 1 |
NCT03140670 | Phase II | Rucaparib | Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy | Terminated | USA | 0 |
NCT03397394 | Phase II | Rucaparib | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS) | Terminated | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT03533946 | Phase II | Rucaparib | Rucaparib in Nonmetastatic prOstAte With BRCAness (ROAR) | Terminated | USA | 0 |
NCT03572478 | Phase Ib/II | Nivolumab + Rucaparib Nivolumab Rucaparib | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | Terminated | USA | 0 |
NCT04171700 | Phase II | Rucaparib | A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR) | Terminated | USA | 0 |
NCT03654833 | Phase II | Bemcentinib + Pembrolizumab Rucaparib Abemaciclib Atezolizumab + Bevacizumab Dostarlimab-gxly + Niraparib | Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (MiST) | Unknown status | GBR | 0 |
CKB CORE allows for only a limited number of monthly page views for un-registered users. However, registration is free and allows for unlimited browsing of the CKB CORE content.
You have reached the monthly page view limit. For continued free access to CKB CORE, please register below: